After participating in this educational activity, attendees should be able to:
1.| Discuss the history of diabetic nephropathy progression over time.
2.| Discuss the ways to use new medications to slow nephropathy progression.
3.| Discuss how to avoid or manage the complications of novel agents approved for slowing nephropathy.
George Bakris, MD
The University of Chicago Medicine
Professor of Medicine
Section of Endocrinology, Diabetes & Metabolism
American Heart Association Comprehensive Hypertension Center
The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Faculty or planner conflicts of interest are resolved before the educational activity.
Dr. Bakris is a consultant for the following companies: Merck, Bayer, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, HOrizon, Novo Nordisk DiaMedica Therapuetics, InRegen
None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 BCIPE Instructional Hours